The stock of Unilife Corp (NASDAQ:UNIS) is a huge mover today! About 133,512 shares traded hands. Unilife Corp (NASDAQ:UNIS) has declined 65.76% since April 5, 2016 and is downtrending. It has underperformed by 67.71% the S&P500.
The move comes after 5 months positive chart setup for the $44.05 million company. It was reported on Nov, 7 by Barchart.com. We have $3.94 PT which if reached, will make NASDAQ:UNIS worth $24.23M more.
Unilife Corp (NASDAQ:UNIS) Ratings Coverage
Out of 3 analysts covering Unilife Corporation (NASDAQ:UNIS), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Unilife Corporation has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was upgraded by Griffin Securities on Monday, January 4 to “Buy”. The company was downgraded on Tuesday, October 20 by Griffin Securities. The rating was downgraded by Piper Jaffray to “Neutral” on Tuesday, March 15. Jefferies downgraded Unilife Corp (NASDAQ:UNIS) on Thursday, August 6 to “Hold” rating. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, September 15. The firm has “Neutral” rating given on Thursday, September 3 by Griffin Securities. Griffin Securities upgraded Unilife Corp (NASDAQ:UNIS) on Wednesday, September 16 to “Buy” rating.
According to Zacks Investment Research, “Unilife Corporation is a medical device company based in U.S., focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. The primary target customers for the Company’s products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife’s main product is the Unifill ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. Unilife Corporation has FDA-registered medical device manufacturing facilities in Pennsylvania.”
More notable recent Unilife Corp (NASDAQ:UNIS) news were published by: Prnewswire.com which released: “Unilife Corporation Provides Business Update” on November 02, 2016, also Streetinsider.com with their article: “Unilife Corp. (UNIS) Issues Accelerated Convertible Note to Amgen” published on October 24, 2016, Reuters.com published: “BRIEF-Unilife Corp announces receipt of delinquency letter from Nasdaq” on September 23, 2016. More interesting news about Unilife Corp (NASDAQ:UNIS) were released by: Reuters.com and their article: “BRIEF-Unilife Corp implemented cost reduction measures” published on October 24, 2016 as well as Prnewswire.com‘s news article titled: “Unilife Corporation Provides Trading Update” with publication date: September 29, 2016.
UNIS Company Profile
Unilife Corporation, incorporated on July 2, 2009, is a medical device maker and component supplier. The Firm is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Firm has a portfolio of product platforms, including pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies who are expected to supply them as drug-device combination products, pre-filled and ready for administration by end users, such as health-care providers or patients. Other of its products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a healthcare well-known provider or end user without having the device pre-filled by a pharmaceutical company.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.